AMBASSADOR Trial: Extended Follow-up on Adjuvant Pembrolizumab in Bladder Cancer
Extended follow-up data from the AMBASSADOR trial shows adjuvant pembrolizumab significantly improves disease-free survival in high-risk muscle-invasive urothelial carcinoma (29.6 vs 14.2 months). Benefits are consistent across PD-L1 status and lymph node involvement subgroups, though overall survival analysis is challenging due to unplanned crossover and patient withdrawals. Pembrolizumab's efficacy is seen in both lower and upper tract urothelial cancers, with common metastatic sites including lymph nodes, bone, liver, and lung. The data supports pembrolizumab as a therapeutic option and highlights the need for biomarkers to optimize patient selection.
Reference News
Extended follow-up data from the AMBASSADOR trial shows adjuvant pembrolizumab significantly improves disease-free survival in high-risk muscle-invasive urothelial carcinoma (29.6 vs 14.2 months). Benefits are consistent across PD-L1 status and lymph node involvement subgroups, though overall survival analysis is challenging due to unplanned crossover and patient withdrawals. Pembrolizumab's efficacy is seen in both lower and upper tract urothelial cancers, with common metastatic sites including lymph nodes, bone, liver, and lung. The data supports pembrolizumab as a therapeutic option and highlights the need for biomarkers to optimize patient selection.